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OBJECTIVES We investigated the potentiation of gene therapy using fibroblast growth factor 4 (FGF4)-
gene by combining plasmid deoxyribonucleic acid (DNA) with biodegradable gelatin
hydrogel (GHG).
BACKGROUND Virus vectors transfer genes efficiently but are biohazardous, whereas naked DNA is safer but
less efficient. Deoxyribonucleic acid charges negatively; GHG has a positively charged
structure and is biodegradable and implantable; FGF4 has an angiogenic ability.
METHODS The GHG-DNA complex was injected into the hindlimb muscle (63 mice and 55 rabbits).
Gene degradation was evaluated by using 125I-labeled GHG-DNA complex in mice.
Transfection efficiency was evaluated with reverse-transcription nested polymerase chain
reaction and X-Gal histostaining. The therapeutic effects of GHG-FGF4-gene complex
(GHG-FGF4) were evaluated in rabbits with hindlimb ischemia.
RESULTS Gelatin hydrogel maintained plasmid in its structure, extending gene degradation temporally
until 28 days after intramuscular delivery, and improving transfection efficiency. Four weeks
after gene transfer, hindlimb muscle necrosis was ameliorated more markedly in the
GHG-FGF4 group than in the naked FGF4-gene and GHG-beta-galactosidase (control)
groups (p  0.05, Kruskal-Wallis test). Synchrotron radiation microangiography (spatial
resolution, 20 m) and flow determination with microspheres confirmed significant vascular
responsiveness to adenosine administration in the GHG-FGF4 group, but not in the naked
FGF4-gene and the control.
CONCLUSIONS The GHG-FGF4 complex promoted angiogenesis and blood flow regulation of the newly
developed vessels possibly by extending gene degradation and improving transfection
efficiency without the biohazard associated with viral vectors. (J Am Coll Cardiol 2003;41:
1056–62) © 2003 by the American College of Cardiology Foundation
Angiogenic gene therapy using growth factors is widely
studied to treat ischemic heart disease and severe limb
ischemia (1,2). Of the two major methods of gene transfer,
the use of virus vectors is efficient but biohazardous (3,4),
while naked deoxyribonucleic acid (DNA) is safer, but less
efficient (5). A highly efficient and safe drug delivery system
without using a virus vector is needed for gene therapy in
humans. We developed a new hydrogel consisting of amino
acids, being biodegradable and, therefore, implantable, from
gelatin (6). Hydrogel has been used to improve transfection
efficiency in a hydrogel-coated balloon catheter (7). How-
ever, this hydrogel was not implantable because it consisted
of carbohydrate and was not biodegradable. The purpose of
the present study is to assess whether biodegradable gelatin
hydrogel (GHG) improves the efficacy of gene therapy with
the fibroblast growth factor 4 (FGF4)/hst1 gene; FGF4 is a
growth factor discovered in human gastric cancer (8) and
has a secretion signal domain (9). Its angiogenic ability has
been confirmed both in vitro and in vivo (10).
METHODS
Experimental animals. All animal experiments were per-
formed in accordance under the Guidelines of Tokai Uni-
versity School of Medicine on Animal Use, which conform
to the National Institute of Health (NIH) Guide for the
Care and Use of Laboratory Animals, DHEW publication
No. (NIH) 86-23, revised 1985, Offices of Science and
Health Reports, DRR/NIH, Bethesda, Maryland. Fifty-five
Japanese white rabbits weighting 2.45 to 2.85 kg (Nihon
Nosan Co., Tokyo, Japan) of both genders were used. The
animals were anesthetized by intravenous injection of so-
dium pentobarbital (40 mg/kg), and hindlimb ischemia was
created by the method of Takeshita et al. (11). Sixty-three
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mice (male ddY mice, six to seven weeks old, Shizuoka
Animal Center, Shizuoka, Japan) were also used.
Preparation of GHG-DNA complex. DNA encoding
FGF4, beta-galactosidase (lacZ) with the cytomegalovirus
enhancer-chicken -actin hybrid promoter comprising a
cytomegalovirus enhancer, and chicken beta-actin promoter
were constructed (12); GHG was prepared from bovine
bone (6). The GHG used in this study was characterized by
a spheroid shape with a diameter of approximately 200 m,
water content of 95%, and an isoelectric point (pI) of 11
after swelling in water, without special statement.
The efficiency of incorporation of DNA into positively
and negatively charged GHG was evaluated. Dried GHG
(4 mg, pI 11 or 5) was added to lacZ DNA solution (500
g/100 l in phosphate-buffered saline [PBS], pH 7.4),
mixed with a vortex mixer for 5 s, and allowed to stand at
37°C; the solution immediately settled. The absorbance
(260 nm) of the supernatant was measured. In a sham
control experiment, GHG was added to pure PBS solution.
Positively charged GHG (pI 11) was immediately impreg-
nated with naked DNA, and was stable at pH 7.4 for at least
120 h, whereas the negatively charged one (pI 5) was not.
Experimental protocols. PROTOCOL 1: DNA DEGRADA-
TION AND THE IMPROVEMENT OF TRANSFECTION EFFI-
CIENCY BY GHG. To examine the temporal extension of
gene degradation by GHG, the decay sequence of 125I-
labeled DNA impregnated into unlabeled GHG, 125I-
labeled GHG, and 125I-labeled DNA solution was com-
pared (63 mice). Plasmid DNA and GHG were
radioiodinated with 125I, with TlCl3 and Bolton and
Hunter reagent (Amersham Pharmacia Biotech Ltd., Buck-
inghamshire, United Kingdom) (13), respectively. To im-
pregnate GHG with DNA, dried GHG (2 mg) was added
to 100 l of naked lacZ solution (50 g/100 l in PBS),
mixed for 5 s, and allowed to stand at 37°C for 2 h. Each
complex was injected into the hindlimb muscle. On days 1,
3, 5, 7, 14, 21, or 28, the muscle was collected, and
radioactivity was measured with a gamma counter (ARC-
301B, Aloka Co., Ltd., Tokyo, Japan) in three mice each.
The following experiment was performed in 16 rabbits to
assess spatial potentiation of gene expression by GHG.
Intramuscular gene transfer was performed 10 days after
modeling hindlimb ischemia. The DNA solution (FGF4-
gene or lacZ 500 g/100 l PBS) mixed with GHG (4 mg;
GHG-FGF4 complex, n  2; GHG-lacZ complex, n  2)
and the original FGF4-gene solution (naked FGF4-gene,
n  2) were diluted with 0.4 ml saline and slowly injected
through a 23-gauge needle at a single point in the adductor
muscle marked with a 4-0 nylon suture. Tissue samples
from the transfected left adductor muscle (the injection site
and the adjacent region 10 mm apart from the injection
site), the right adductor muscle, stomach, liver, spleen,
testes, kidneys, heart, lungs, and brain were retrieved and
immediately frozen in liquid nitrogen on day 17; FGF4-
gene expression was evaluated by reverse transcription-
nested polymerase chain reaction (RT-nested PCR). In the
remaining 10 rabbits, gene expression was evaluated with
lacZ gene; GHG-lacZ complex (n  5) and naked lacZ
solution (n  5) were injected at a single point in the
adductor muscle in the same way as the GHG-FGF4
injection on day 10. On day 17, a muscle sample at the
injection site was dissected out, and expression of lacZ was
determined by X-Gal histostaining (14).
PROTOCOL 2: SALVAGE OF HINDLIMB ISCHEMIA WITH GHG-
PLASMID COMPLEX ENCODING FGF4. The angiogenic effect
of three sets of GHG-DNA complexes were compared in
39 rabbits with hindlimb ischemia: 1) GHG impregnated
with lacZ plasmid (GHG-lacZ: control); 2) naked FGF4-
plasmid (naked FGF4-gene); and 3) GHG impregnated
with FGF4 plasmid (GHG-FGF4). The amount of plas-
mid was 500 g (1.0 ml) and that of GHG was 4 mg. On
day 10 of ischemia, the gene complex was injected at five
points 20 mm apart in the adductor muscle with a 23-gauge
needle.
In 18 rabbits, on days 10 and 38 of ischemia, calf systolic
blood pressure was measured by the Doppler flow signal
from the posterior tibial artery (ES-100V2, Hayashi Denki
Co., Kawasaki, Japan) with a 25-mm wide cuff. The calf
blood pressure ratio of each rabbit was defined as the ratio
of the systolic pressure of the ischemic limb to that of the
normal limb. Regional blood flow was measured by the
microsphere method (15) at baseline on days 0 and 38. On
day 38, adenosine (100 g/kg/min) was administered 30
min after baseline flow measurement (vasodilatory condi-
tion). A 4F catheter was introduced into the ascending aorta
via the common carotid artery for microsphere injection and
adenosine administration. Microspheres (15-m diameter,
3  106) labeled with one of four sets of stable heavy
elements (In, I, Ba, or Ce, Sekisui Plastic, Osaka, Japan)
(15) were suspended in 0.05% sodium dodecyl sulfate at a
concentration of 5  106/ml and injected into the ascend-
ing aorta. After killing the animals, the adductor, semimem-
branous, and gastrocnemius muscles were dissected out and
weighed. The X-ray fluorescence of the labeled micro-
spheres was measured in 4 to 8 g of the dissected muscles to
calculate the regional blood flow (15) and expressed as the
ratio of flow in the ischemic limb to flow in the normal limb.
Abbreviations and Acronyms
ANOVA  analysis of variance
cDNA  complementary deoxyribonucleic acid
DNA  deoxyribonucleic acid
FGF4  fibroblast growth factor 4
GHG  gelatin hydrogel
lacZ  beta-galactosidase
NIH  National Institute of Health
PBS  phosphate-buffered saline
pI  isoelectric point
RNA  ribonucleic acid
RT-nested PCR  reverse transcription-nested
polymerase chain reaction
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Sufficient mixing of microspheres injected into the aorta
(not into the left atrium) was confirmed by a preliminary
study in which two different sets of microspheres were
simultaneously injected into the aorta. The liner regression
analysis on the two different sets of flows yielded an almost
identical regression line (y  1.011x  0.003, r  0.98, Sy
· x  0.032 ). The remaining muscle tissue was used for
histological analysis. An investigator blinded to the treat-
ment macroscopically evaluated the ischemic limb on
graded morphological scales for area of muscle necrosis (the
adductor, semimembranous, medial large, and gastrocne-
mius muscles; grade 0 to 5; Table 1).
Synchrotron radiation microangiography characterized by
high-resolution and high-sensitivity (16) was performed in
21 rabbits as previously described (15,17,18). The system is
capable of separating adjacent lead lines only 20 m apart
on the resolution bar chart with 640 higher sensitivity
than charge-coupled device camera system. This system
allows detection and functional analysis of small vessels with
a diameter of 200 to 500 m in situ (15,17,18). Contrast
material containing 37% nonionic iodine (Iopamidol, Ni-
hon Schering Co., Tokyo, Japan) was injected via a 4F
catheter placed immediately above the aortic bifurcation
under baseline condition and during adenosine administra-
tion (100 g/kg/min) (vasodilatory condition) via the same
catheter. Vessel density in the midzone collateral was
evaluated as an angiographic score (11,15,18).
Plasmid. Complementary deoxyribonucleic acid (cDNA)
of human hst1/FGF4 (19), or bacterial -galactosidase was
inserted into the expression vector pRC/CMV (Invitrogen
Corp., Carlsbad, California) and designated as pRC/CMV-
HST1-10 (human stomach tumor) and pRC/CMV-lacZ,
respectively. Preparation and purification of the plasmid
from cultures of pRC/CMV-HST1-10-, or pRC/CMV-
lacZ-transformed Escherichia coli were performed by cen-
trifugation to equilibrium in cesium chloride-ethidium bro-
mide gradients.
RT-nested PCR. Ribonucleic acid (RNA) was extracted
from tissues with ISOGEN (Nippon Gene, Tokyo, Japan).
The extracted RNA was treated with DNase twice to
eliminate DNA contamination. In each set of experiments,
0.5 g of total RNA was denatured at 70°C for 5 min, and
reverse transcription was carried out at 37°C for 60 min;
RT-nested PCR was carried out in a thermal cycler
(GeneAmp PCR System 9600, Perkin Elmer, Wellesley,
Massachusetts) with primers designed to selectively amplify
the FGF4 cDNA. The external primers EcoHST1f3 (for-
ward primer: GGA ATT CAC TGA CCG CCT GAC
CGA CGC ACG GCC CTC G) and SalHST1r2 (reverse
primer: GCG TCG ACC CCG AGG CTG AGG CAA
GGG TCC TCT) were used for the first round (generating
a 704-base pair [bp] fragment). The second round of the
amplification (nested PCR) was performed with two inter-
nal primers HST1LGC1 (forward primer: AGC TCT
CGC CCG TGG AGC GG) and HST1AA-r (reverse
primer: CTC TGG AGG GTC ACA GCC TG) (gener-
ating a 282-bp fragment). The PCR reactions were per-
formed as follows. The thermal cycle conditions for the first
round were 30 cycles (95°C for 1 min, 59°C for 1 min, 72°C
for 1 min), and for the second round were 25 cycles (94°C
for 1 min, 72°C for 2 min), followed by incubation at 72°C
for 10 min, respectively. Amplification products were de-
tected after electrophoresis on 3.5% agarose gels by staining
with ethidium bromide. A primer set of beta-actin (gener-
ating a 506-bp fragment) was used as a positive control for
RT-PCR analysis.
Statistical analysis. Data are presented as mean values 
SD. Differences were assessed by using the paired t test,
Kruskal-Wallis test, or analysis of variance (ANOVA) for
factorial or repeated measures with the Scheffe´ F test when
applicable. A value of p  0.05 was considered statistically
significant.
RESULTS
Protocol 1: DNA degradation and the improvement of
transfection efficiency by GHG. The radioactivity of ra-
diolabeled DNA impregnated into GHG in the limb
muscle remained above the detection limit for four weeks
(solid line in Fig. 1). The radiolabeled DNA impregnated
into GHG had decay sequences almost identical to those of
the radiolabeled GHG (dotted line in Fig. 1). By contrast,
the radioactivity of naked DNA (dashed line in Fig. 1)
decreased to 10% of the baseline within a day.
Gelatin hydrogel improved transfection efficiency in vivo;
RT nested-PCR analyses revealed FGF4 expression at all
injection sites in the left adductor muscle in the FGF4-
gene-treated animals (n  4), as shown in lanes 1 (naked
FGF4-gene) and 4 (GHG-FGF4) in Figure 2; FGF4
expression was also detected in the adjacent region 10 mm
apart from the injection site in the left adductor muscle in
the GHG-FGF4-treated animals (lane 5), but not in the
naked FGF4-gene-treated animals (lane 2). No expression
was detected in any animal at remote sites, such as the right
adductor muscle (lanes 3 and 6), stomach, liver, spleen,
Table 1. Morphologic Evaluation of Gene Therapy
Muscle Necrosis
(Area) GHG-lacZ
Naked
FGF4 GHG-FGF4*†
Grade 0 (0 cm2) 0 0 0
Grade 1 (1 cm2) 0 0 50% (3/6)
Grade 2 (3 cm2) 17% (1/6) 33% (2/6) 50% (3/6)
Grade 3 (5 cm2) 0 67% (4/6) 0
Grade 4 (10 cm2) 50% (3/6) 0 0
Grade 5 (10 cm2) 33% (2/6) 0 0
Muscle weight ratio (%) 48  67 (6) 62  14 (6) 79  11* (6)
Morphologic indexes in 18 gene-transferred rabbits on day 38. The ischemic limb was
macroscopically evaluated by using graded morphological scales for muscle necrosis
area (the adductor, semimembranous, medial large, and gastrocnemius muscles)
(grade 0 to 5); GHG-FGF4 group had significantly less muscle necrosis compared
with naked FGF4 and GHG-lacZ groups. Muscle weight ratio was significantly
different between GHG-FGF4 and GHG-lacZ groups. p  0.05 vs. *GHG-lacZ,
†naked FGF4 (Kruskal-Wallis test, analysis of variance).
FGF4  fibroblast growth factor 4; GHG  gelatin hydrogel; lacZ 
-galactosidase.
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testes, kidneys, heart, lungs, or brain (data not shown);
lacZ-treated animals showed no FGF4 expression at any
sites (lanes 7 and 8). Beta-actin expression was detected in
all samples (lower panel), but neither beta-actin nor FGF4
expression was detected in any control samples that were not
treated with reverse transcriptase; lacZ expression of naked
DNA (500 g) was localized to the injection site (Fig. 3A),
whereas GHG-DNA complex (DNA amount 500 g)
showed a spatially expanded expression on day 17 (Fig. 3B).
The degree of gene expression in myocytes was also aug-
mented by GHG.
Protocol 2: salvage of hindlimb ischemia with GHG-
plasmid complex encoding FGF4. Functional evaluation
of ischemic hindlimbs showed amelioration of the ischemia
by the FGF4-gene and potentiation of the amelioration
when GHG was used as a delivery device. The augmenta-
tion of regional blood flow with GHG was more evident
under vasodilatory conditions than at the baseline.
Regional blood flow analysis and angiographic analysis
further confirmed the background mechanism for amelio-
ration of hindlimb ischemia by GHG-FGF4 (Table 2). On
day 38, blood flow during adenosine administration (vaso-
dilatory condition) in the GHG-FGF4 group (105  13%
in terms of ischemic/normal flow ratio) was significantly
higher than in either the naked FGF4-gene group (68 
18%, p  0.05) or the GHG-lacZ group (50  12%, p 
0.05, ANOVA). The differences between the naked FGF4-
gene and GHG-lacZ groups were not significant
(ANOVA). The adenosine-dependent flow-augmentation
(responsiveness to vasodilatory stimulation; comparison be-
tween adenosine and baseline values on day 38) was noted
only in the GHG-FGF4 group (from 79  16% to 105 
13%, p  0.05, ANOVA), and not in the other two groups.
A similar tendency was noted in flow under baseline
conditions on day 38 in all three groups; however, the
Figure 1. Decay sequences of radiolabeled deoxyribonucleic acid (DNA),
gelatin hydrogel (GHG), and DNA combined with GHG in the hindlimb
muscles of mice. Unlabeled GHG impregnated with 125I-labeled DNA
(solid line), 125I-labeled GHG (dashed line), and 125I-labeled DNA
solution (dotted line) were injected into the hindlimb muscles.
Figure 2. Representative transgene expression demonstrated by reverse-
transcription nested polymerase chain reaction (RT-nested PCR). The left
adductor muscle of the rabbits was injected with naked fibroblast growth
factor 4 (FGF4) gene (lanes 1 to 3), gelatin hydrogel (GHG)-FGF4 (lanes
4 to 6), or GHG-lacZ (lanes 7 and 8). Each sample was obtained from the
injection site (lanes 1, 4, and 7) and the adjacent region 10 mm apart from
the injection site (lanes 2, 5 and 8) in the left adductor muscle, and from
the contralateral adductor muscle (lanes 3 and 6). The RT-nested PCR
products from ribonucleic acid of each sample were analyzed on agarose
gel; FGF4 expressed Cc1/l6 cells as a positive control (lane 9) and no
deoxyribonucleic acid (DNA) template as a negative control (lane 10). A
housekeeping beta-actin gene was amplified as a complementary DNA
loading control.
Figure 3. Representative gene expression of lacZ in the ischemic adductor
muscle in rabbits on day 17. Naked deoxyribonucleic acid (DNA) (A) or
gelatin hydrogel-DNA complex (B) was injected into the adductor muscle
10 days after the ischemic insult. X-Gal stain; original magnification 20;
bar  200 m.
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differences in baseline flow among the three groups were less
marked than during adenosine administration.
Synchrotron radiation microangiography revealed mi-
crovessel responsiveness to the vasodilatory stimulation in
the GHG-FGF4-treated rabbits (Figs. 4C and 4D),
whereas vascular density was somewhat decreased by aden-
osine treatment in some of the GHG-lacZ-treated rabbits
(Figs. 4A and 4B). Angiographic score analysis yielded
quantitative evidence (Table 2). The angiographic score
during adenosine administration (vasodilatory condition)
was significantly higher in the GHG-FGF4 group (0.56 
0.15) than in either the naked FGF4-gene group (0.41 
0.13, p  0.05) or the GHG-lacZ group (0.36  0.10, p 
0.05, ANOVA). By contrast, under baseline conditions, the
angiographic scores of the three groups were not signifi-
cantly different.
On day 38, the GHG-FGF4 group had the highest
calf-blood pressure ratio (70 11%), and it was lower in the
naked FGF4-gene group (63  6%), and even lower in the
GHG-lacZ group (56  4%, p  0.05 vs. the GHG-lacZ
group, ANOVA, Table 2). On day 10 (the time of gene
transfer), the degrees of decrease in the three groups were
not significantly different (26% to 33% in the mean).
Tissue damage was least in the GHG-FGF4-treated
rabbits (Table 1). Limb muscle necrosis was 3 cm2 and
grade 1 or 2 in all of the animals in the GHG-FGF4 group,
and significantly less than in the other two groups (p 
0.05, Kruskal-Wallis test). A similar difference was noted in
the degrees of toe necrosis (data not shown). The muscle
weight ratio (ischemic/normal) on day 38 was highest in the
GHG-FGF4 group (79  11%), lower in the naked
FGF4-gene group (62  14%), and even lower in the
GHG-lacZ group (48  67%), and the difference between
the GHG-FGF4 group and GHG-lacZ group was signif-
icant (p  0.05, ANOVA). The muscle weight ratio values
(a morphological index) positively correlated with vascular
responsiveness to adenosine (adenosine/baseline blood flow
ratio [%]; a functional index) (r  0.50, n  18, Sy · x 
0.15, Sy · x/y  0.23, p  0.045). Thus, the blood flow,
microangiographic, and morphologic analyses demonstrated
a greater ameliorative effect of the GHG-FGF4 complex
compared with the naked FGF4-gene (Tables 1 and 2).
Minimal inflammatory infiltrates, such as neutrophil and
lymphoplasmacytic cell infiltrates, were noted at the injec-
tion site, but histological analysis showed that the infiltrates
were localized. There was no evidence of fibrous prolifera-
tion or tumor formation in the transfected muscles or in
other organs (right adductor muscle, stomach, liver, spleen,
testes, kidneys, heart, lungs, and brain) in any of the groups.
DISCUSSION
We demonstrated that GHG potentiated the angiogenic
effect of the FGF4-gene (protocol 2) by prolonging DNA
degradation and improving transfection efficiency (protocol
1). Thus, GHG might facilitate the gene therapy of
intractable circulatory disorders with genes for angiogenic
growth factors.
Gelatin hydrogel augmented the effect of the FGF4-gene
Table 2. Functional Evaluation of Gene Therapy
GHG-lacZ Naked FGF4 GHG-FGF4
Blood flow ratio (%) (ischemic/normal)
Day 0 (BL) 33  8 (6) 36  11 (6) 37  10 (6)
Day 38 (BL) 47  12‡ (6) 58  16‡ (6) 79  16*‡ (6)
Day 38 (Ad) 50  12‡ (6) 68  18‡ (6) 105  13*†‡§ (6)
Angiographic score
Day 38 (BL) 0.37  0.12 (7) 0.39  0.13 (7) 0.42  0.11 (7)
Day 38 (Ad) 0.36  0.10 (7) 0.41  0.13 (7) 0.56  0.15*†§ (7)
Blood pressure (%) (ischemic/normal)
Day 10 31  8 (6) 33  5 (6) 26  7 (6)
Day 38 56  4 (6) 63  6 (6) 70  11* (6)
Angiographic score was calculated on the synchrotron radiation microangiogram. p  0.05 vs. *GHG-lacZ, †naked FGF4, ‡day
0 (BL), and §day 38 (BL) (analysis of variance).
Ad during adenosine administration; BL under baseline condition; FGF4 fibroblast growth factor 4; GHG gelatin
hydrogel; lacZ  -galactosidase.
Figure 4. Representative synchrotron radiation microangiograms of the
hindlimb ischemia in the rabbits. Synchrotron radiation microangiograms
were taken under baseline conditions (A and C) and after repeated
adenosine administration (B and D) on day 38. (A and B) Gelatin
hydrogel (GHG)-lacZ-treated rabbit; (C and D) GHG-fibroblast growth
factor 4-treated rabbit. Arrows indicate the same point in the vessels.
Arrowheads reference copper wires with a diameter of 130 m; bar 1 mm.
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therapy by improving gene biodegradation and transfection
efficiency. We demonstrated that GHG rapidly absorbed
plasmid DNA and did not release it in vitro (see Methods
section). In the radioiodine experiment, the radioactivity of
naked DNA was reduced to less than 10% of the baseline
within a day, whereas the radioactivity of DNA impreg-
nated into GHG remained for four weeks (Fig. 1). In the
experiment using the rabbit hindlimb ischemia model, the
PCR analysis suggested that GHG expanded the gene
transfer spatially (lanes 2 and 5 in Fig. 2). The maker gene
experiment (protocol 1) confirmed that the use of GHG
augmented both the number of transfected myocytes and
the degree of gene expression in these cells, and also
supported the spatially expanded gene expression (Fig. 3).
The superiority of the therapeutic effects of the GHG-
FGF4-gene complex on hindlimb ischemia compared with
naked FGF4-gene treatment was confirmed in the rabbit
experiments in protocol 2 (Fig. 4, Tables 1 and 2); GHG-
FGF4-treated rabbits were characterized by less severe
tissue damage in the ischemic limb (Table 2) and more
marked vascular responsiveness to adenosine than either the
naked FGF4-treated or GHG-lacZ-treated rabbits (Fig. 4,
Table 2, Protocol 2 in the Results section). Under the
baseline conditions, blood flow in normal muscle tissue is set
at a relatively low level in preparation for an abrupt increase
in flow demand (approximately 5 and 30 in the heart
and in the skeletal muscle, respectively) during exercise, etc.
(responsiveness to the vasodilatory stimulation). In other
words, normal muscle tissue has a sufficient flow reserve
(20,21), and, thus, the presence or absence of vascular
responsiveness to adenosine administration can be used as
an index of fundamental vascular function in angiogenic
vascular segments. The demonstration of a positive corre-
lation between flow responsiveness to adenosine and the
muscle weight ratio further supports our hypothesis. Base-
line flow may reflect the total number of angiogenic vessels,
if it does not respond to vasodilatory stimulation. However,
if the vasodilatory mechanism is present, baseline flow alone
does not necessarily reflect the quality and/or quantity of
angiogenic vascular segments. The amelioration of the
ischemic tissue in the GHG-FGF4 group may be related to
an adequate flow reserve (20,21) of so-called “well-tempered
angiogenic vessels” (22).
Consequently, GHG offers several advantages as a new
gene delivery system: 1) it has a positively charged structure,
so it holds negatively charged nucleic acids, proteins, and
drugs within its structure; 2) GHG is biodegradable and
implantable; the biodegradable nature is from the gelatin
itself but not from the hydrogel state. The substance bound
to the GHG is gradually released as the gelatin degrades in
situ. The degradation period can be adjusted to two to four
weeks by varying the water content. Thus, the prolonged
release of the DNA held in GHG was presumably respon-
sible for the augmentation of gene therapy. The use of
hydrogel-coated balloon-angioplasty-catheter has been re-
ported (7). However, this gel is much different from our
hydrogel. The present GHG consists of amino acids and is
biodegradable and implantable, whereas their hydrogel con-
sists of carbohydrate and is not biodegradable nor implant-
able. 3) The isoelectric point and the shape of the GHG can
be modified. Negatively charged GHG holds positively
charged substances such as basic-FGF protein (6,23), and
disk-shaped GHG has been found to be effective for
reconstruction of bone defects (23); 4) GHG is less biohaz-
ardous than adenovirus vectors. Gelatin is already used in
the clinical field, and its safety is established. Thus, the use
of GHG with naked DNA improves its transfection effi-
ciency without causing serious cytotoxicity or biohazards,
which are inconvenient side effects of virus vectors (24).
Therefore, the nonvirus vector GHG is useful for various
gene therapies including the treatment of cardiovascular
disorders.
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